GERON CORP
GERN · XNASCIK 886744fmd_0A5DHFEHZDDDHZE9B62MSJMCEXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | – | – |
| Research and development | 18 | 11 | 13 | 52 | 51 | 86 | 96 | 125 | 104 | 71 |
| Selling, general and administrative | – | – | – | – | – | – | 44 | 69 | 146 | 159 |
| Total operating expenses | 37 | 30 | 32 | 73 | 77 | 115 | 139 | 194 | 251 | 252 |
| Operating income | (31) | (29) | (31) | (73) | (77) | (114) | (139) | (194) | (174) | (69) |
| Interest expense | – | – | – | – | 1 | 4 | 7 | 8 | 19 | 33 |
| Interest and investment income | 1 | 1 | 3 | 4 | 2 | 1 | 3 | 18 | 20 | 18 |
| Other non-operating income (expense) | – | – | (0) | (0) | 0 | 1 | 1 | (0) | (0) | (0) |
| Income before taxes | – | – | – | – | – | – | (142) | (182) | (175) | (83) |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (182) | (175) | (84) |
| Net income | (30) | (28) | (27) | (69) | (76) | (116) | (142) | (184) | (175) | (84) |